본문 바로가기 주메뉴 바로가기
2016 HiVF

2016 HiVF

2016 HiVF Program

Date Time Contents
Day 1
6.10
(Fri)
08:30~09:00 Registration
09:00~09:30 Opening Ceremony
09:30~10:15
Plenary lecture
Chair: Joon Haeng Rhee (Organizing Chair, 2016 HIVF)
Why is an anti-Ebola or MERS vaccine easy
but "impossible" against HIV or TB?
Professor Rolf Zinkernage
10:15~10:30 Break
10:30~12:10
Session 1. Vaccine Science and Technology I
Chair: Senyon Choe (President, Mogam Institute)
DNA Vaccine: Past, Present and Future
Professor Young-Chul Sung
Universal Influenza Vaccine: Hype or Hope?
Professor Baik Lin Seong
Novel Recombinant Subunit Vaccines with Intrinsic Adjuvant
Dr. Pele chong
12:10~13:10 Luncheon
13:10~15:00
Session 2.Vaccine Policy and Global Community
Chair: Frank Emmrich (Director, Fraunhofer IZI)
A World of Good: Partnering to Support Global Health
Dr. Peter Khoury
Ethical Issues and Challenges for Global Vaccines
Dr. Margaret Liu
Vaccines for Global Health: IVI & Typhoid Conjugate Vaccine Development
Director General Jerome Kim
15:00~15:15 Break
15:15~17:45
Session 3.Vaccine Science and Technology II
Chair: Hyeong-Joon Kim (Director, CNU Hwasun Hospital)
MucoRice and NanoGel:
New Generation of Mucosal Vaccines for Aero-digestive Infectious Diseases
Professor Hiroshi Kiyono
CVD 103-HgR, a single-dose live oral cholera vaccine for travelers and for reactive immunization to control "virgin soil" epidemics in immunologically-naive populations"
Professor Myron Levine
Immunology of Vaccination
Professor Rafi Ahmed
The Design and Role of Public Vaccine Development and Support Center in KNIH
Director Won Keun Seong
17:45~17:55
Closing Ceremony
Remark
HIVF 2016 Organizing Chair Joon Haeng Rhee
Day 2
6.11
(Sat)
08:30~09:00 Registration
09:00~11:00
Roundtable Discussion
Perspectives on national and international vaccines
11:00~12:00 Technical Tour - Hwasun Plant of Green Cross Corp / Biopharmaceutical Research Center
12:00~13:00 Luncheon

2016 HiVF Speakers

Rolf Martin Zinkernagel (M.D.  Ph.D.)

Learn more

Rolf Martin Zinkernagel (M.D.  Ph.D.)

Nobel Prize in Physiology
or Medicine

1996 with Peter C. Doherty (AAI '76)
“For their discoveries concerning the specificity of the cell mediated immune defense.”

Albert Lasker Basic Medical Research Award

1995 “For the landmark discovery of MHC restriction of T-cell recognition, and the altered-self hypothesis.”

Biography

Zinkernagel was born in Riehen, Switzerland, on January 6, 1944. After earning his M.D. from the University of Basel in 1970, he received a two-year postdoctoral fellowship in the Department of Biochemistry at the University of Lausanne. He began his training in immunology at Lausanne and learned first-hand the "frustrations of experimental lab work" while attempting to measure the radioactivity of cells infected by bacteria. In 1972, after taking a World Health Organization course on immunology taught by visiting professor Robert V. Blanden (AAI '77) at Lausanne, Zinkernagel applied for a second postdoctoral fellowship at the John Curtin School of Medical Research at Australian National University in Canberra, Australia, where he planned to study cell-mediated immunity to Listeria and Salmonella under Blanden. When Zinkernagel arrived in Canberra in January 1973, however, the only laboratory with available space was that occupied by another postdoctoral fellow—Peter Doherty. Shortly thereafter, Zinkernagel and Doherty began collaborating on the study of the immune response to LCMV, for which they were awarded the Nobel Prize.


Although Zinkernagel had not originally intended to pursue another degree when he moved to Australia, shortly after he began collaborating with Doherty, he entered the graduate immunology program at Australian National University, earning his Ph.D. in 1975. Recruited by Frank Dixon (AAI '50, president 1971–72), Zinkernagel accepted a position as an associate member of the Scripps Clinical Research Institute in La Jolla, California, in 1976. He also began teaching in the Department of Pathology at the University of California, San Diego. Shortly after being promoted to the rank of full member at Scripps in 1979, he returned to Switzerland to join the faculty of the Department of Pathology at the University of Zurich as associate professor. Promoted to full professor in 1988, Zinkernagel was appointed founding co-director of the university's Institute of Experimental Biology in 1992. He retired from both positions in 2008.

Myron M. Levine (M.D.  D.T.P.H.)

University of Maryland School of Medicine USA

Learn more

Myron M. Levine (M.D.  D.T.P.H.)

University of Maryland School of Medicine USA

Biography

Dr. Myron M. Levine is the Bessie & Simon Grollman Distinguished Professor at the University of Maryland School of Medicine, Associate Dean for Global Health, Vaccinology and Infectious Diseases, and the Founder and Former Director of the Center for Vaccine Development (1974-2014). He is clinically trained in pediatrics and pediatric infectious diseases and in tropical public health and epidemiology. He has extensive experience in design and evaluation of vaccines to prevent bacterial enteric infections, and has made substantial contributions in basic vaccinology, bacterial pathogenesis, clinical research, field epidemiology and public health. Dr. Levine has 46 years of continual involvement in conducting Phase 1, 2, 3 and 4 clinical trials to evaluate the safety, immunogenicity and efficacy of a wide array of vaccines. Besides serving as a clinician in vaccine testing (for both adults and children) and designing and supervising epidemiologic studies (conducted in the U.S. and abroad), he supervises laboratory research activities. Dr. Levine has published over 600 peer reviewed journal articles, is an inventor or co-inventor on many issued patents and is Senior Editor of New Generation Vaccines, 4th ed, a textbook of research vaccinology. A few of his achievement awards include the Albert B. Sabin Gold Medal Award for lifetime achievement in vaccine development and implementation, ASM’s 2012 Maurice Hilleman/Merck Award, Donald Mackay Medal of the American Society of Tropical Medicine and Hygiene, American College of Physicians Award for Outstanding Work in Science as Related to Medicine, and is a member of the National Academy of Medicine, USA.

Ahmed, Rafi

Director of Emory Vaccine Center

Learn more

Ahmed, Rafi

Director of Emory Vaccine Center

Personal Statement

1968 B. Sc. Osmania University, Hyderabad, India Chemistry

1972/1974 B.S./M.S., Idaho State University, Pocatello, Idaho Microbiology

1981 Ph.D. Harvard University, Cambridge, MA Micro. & Molec. Gen.

1981-84 Post-doc Scripps Clinic & Research Foundation Immunology


My research efforts are directed towards: 1. Understanding the mechanisms of immunological memory and using this knowledge to develop new and more effective vaccines. 2. Defining the mechanisms of T cell exhaustion during chronic viral infections and cancer and developing strategies for restoring function in exhausted T cells.

Positions and Honors
Positions and Employment

1984 Assistant Member, Dept. Immunology, Scripps Clinic and Research Foundation, La Jolla, CA

1984-1988 Assistant Professor, Dept. Microbiology and Immunology, UCLA School of Medicine

1988-1992 Associate Professor, Dept. Microbiology and Immunology, UCLA School of Medicine

1992-1995 Professor, Dept. of Microbiology and Immunology, UCLA School of Medicine

1995-Present Georgia Research Alliance Professor of Vaccinology, Emory University

1995-Present Director, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA

Honors

2004 Fellow, American Academy of Microbiology

2009 Member, National Academy of Sciences (USA)

2013 Foreign Member,Indian National Academy of Sciences

2014 Member, National Academy of Medicine (USA)

2015 AAI Excellence in Mentoring Award

Scientific Advisory Boards

1998-Present SAB, Ministry of Science, Dept. of Biotechnology, Gov. of India, New Delhi, India

2006-Present Scientific Advisory Board, Singapore-MIT Alliance for Research & Technology, Cambridge, MA

2007-Present NIH Vaccine Research Center, Board of Scientific Counselors, Bethesda, MD

2008-Present Immune Design, Seattle WA

2008-Present Selecta Biosciences, Boston, MA

2014–Present Scientific Advisory Board, La Jolla Institute for Allergy & Immunology, La Jolla, CA

2014-Present Merck Pharmaceutical, West Point, PA

Contribution to Science

Dr. Ahmed’s work has been highly influential in shaping our current understanding of memory T cell differentiation and anti-viral T and B cell immunity. Dr. Ahmed’s group revealed mechanisms by which long-term immune memory is maintained after vaccination and defined the underlying causes of T cell dysfunction during chronic infection. Dr. Ahmed’s work identified PD-1 as a major regulator of T cell exhaustion. This work has resulted in the development of strategies for the treatment of human chronic infections and cancer.

Complete List of Published Work in MyBibliography: http://www.ncbi.nlm.nih.gov/sites/myncbi/rafi.ahmed.1/bibliography/41160415/public/?sort=date&direction=ascending

Research Support (Active)

1U01AI115651 (Ahmed) 12/01/14–11/30/19

ICIDR: Dengue Virus Infection in India

The major goal of this grant is to: (i) build capacity for dengue research in India using state of the art tools and technologies; and (ii) To address critical scientific questions important to the health and well being of dengue exposed population in India.


2 R01 AI030048-23 (Ahmed) 07/01/90-02/29/17

NIH/NIAID

T Cell Memory to Viruses

The major goal of this project is to understand the mechanisms by which long-term T cell memory is generated and maintained.


5 U19 AI057266 (Ahmed) 09/01/03-04/30/19

NIH/NIAID

Vaccine Induced Immunity in the Young and Aged

This is a Human Immunology Center grant to support studies characterizing immunological memory in humans after vaccination.


1 U19 AI090023 (Pulendran) 07/12/2010-06/30/20

NIH/NIAID

System Biological Analyses of Innate and Adaptive Responses to Vaccination

The major goal of this project to use a “systems vaccinology” approach to probe the immune response to vaccination in special populations, who are at the “extremes of age,” and immunocompromised. This project will evaluate the adaptive immune responses to the VZV and pneumococcal vaccines.


HHSN266200700006C (Orenstein) 03/2007-03/29/21

NIH/NIAID

NIAID Center of Excellence for Influenza Research and Surveillance

The major goal of this contract is to characterize the humoral response to the influenza vaccine.


5 P01 AI056299 (Sharpe) 09/30/03-08/31/19

Harvard University (NIH/NIAID)

T Cell Costimulatory Pathways: Functions and Interactions

The major goal of this project is to analyze how PD-1 and its ligands regulate humoral immunity during acute viral infection.


1 P01 AI097092-01A1 (Palese) 07/01/12-06/30/17

Towards a Universal Influenza Virus Vaccine (NIH/NIAID)

The major goal of this grant is to develop a universal influenza vaccine that would confer long-live protective immunity.


W31P4Q-14-1-0010 (Ahmed) 09/22/14–02/11/18

DARPA

Development of Antibody Therapeutics against Ebola

The major goal of this grant is to develop therapeutic antibodies against Ebola virus. The Ahmed group will generate and characterize Ebola-specific human antibodies from patients that have been infected with Ebola virus.

Margaret Ann Liu (M.D.  D.Sc.)

Executive Vice-Chair of International Society of Vaccines

Learn more

Margaret Ann Liu (M.D.  D.Sc.)

Executive Vice-Chair of International Society of Vaccines

Biography

Margaret A. Liu, obtained an M.D. from Harvard Medical School, in addition to a B.A. in Chemistry, summa cum laude, from Colorado College, and passed the Epreuve pour le Diplômed’Enseignement, à l’unanimité (judges’ unanimous decision), in piano from the EcoleNormale de Musique de Paris. She completed Internship and Residency in Internal Medicine and a Fellowship in Endocrinology, all at Massachusetts General Hospital/Harvard Medical School. She received Board Certification in Internal Medicine and in Endocrinology and Metabolism. Dr. Liu was a Visiting Scientist at the Massachusetts Institute of Technology, Instructor at Harvard Medical School, Adjunct Assistant Professor of Medicine at the University of Pennsylvania, a Visiting Professor at the Karolinska Institutet in Stockholm, and the recipient of an NIH Physician Scientist Award. She served as Senior Director at Merck Research Laboratories, Vice President of Vaccines Research and Gene Therapy at Chiron Corporation, Vice-Chairman of Transgène, Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation, and Executive Vice-Chair of the International Vaccine Institute (IVI) in Seoul, Korea. Dr. Liuconsultsin the fields of vaccines and immunotherapy for companies, universities, and non-governmental and scientific governmental organizations, and is a Foreign Adjunct Professor at the Karolinska Institutet in Stockholm, and an Adjunct Full Professor at the University of California, San Francisco.She is President of the International Society for Vaccines.

Board positions have included: the NIH NIAID Council (an appointment made by the US Secretary of Health and Human Services), Vice-Chairmanship of the Board of Trustees of the IVI (having been the chairman of the Scientific Advisory Group of IVI, 2000-06), the European Developing Country Clinical Trials Partnership (EDCTP) Board (based in The Hague), the Board of Directors of Keystone Symposia (where she was chair of the Development Committee),the Advisory Council and Board of Directors of the American Society of Gene Therapy,Trustee and Treasurer of the San Francisco Conservatory of Music, a member of the review panel of the Chinese Academy of Sciences for the Institute Pasteur, Shanghai,and the board of Sangamo Biosciences. Other present and/or past advisory board roles have included: core membership of the R&D working group of the Bill & Melinda Gates Foundation Decade of Vaccines Collaboration, and international advisor for the National Engineering Laboratory for Therapeutic Vaccines, (Shanghai, China), the Scientific Advisory Board of the Jenner Vaccine Institute (Oxford, U.K.), membership on the panel that evaluated clinical research in Sweden and Finland for the Swedish Research Council and the Academy of Finland, the evaluation panel for the GLOBVAC program for the Research Council of Norway, the External Scientific Advisory Committee of the European Malaria Vaccine Development Agency, the NIH NIAID AIDS Vaccine Research Subcommittee, scientific advisor for AVAC (the AIDS Vaccine Advocacy Coalition), the Advisory Board for the Elizabeth Glazer Pediatric AIDS Foundation Scholars Award, the faculty of Europrise, the Advisory Board of AVIP (European AIDS Vaccine Integrated Program), TBVAC,the External Scientific Advisory Committee of the Children’s Hospital Oakland Research Institute, the Institute of Medicine’s committee that reviewed the Department of Defense Malaria Vaccine, the WHO IVR VAC ( WHO’s Initiative for Vaccine Research, Vaccine Advisory Committee), and the GAVI R&D Task Force.In addition she was a consultant to the U.S. National Academy of Science Institute of Medicine’s committee reviewing the US National Vaccine Plan (having declined an invitation to membership on the committee), and has advised scientists of the Bill & Melinda Gates Foundation Grand Challenges for Global Health.

She is a founding editor or on the editorial board or editorial advisory board of various scientific journals. Dr. Liu has been elected a member of the American Society for Clinical Investigation, a Fellow of the Molecular Medicine Society and of the International Society for Vaccines, and received an honorary Doctorate of Science from Colorado College in 2002. She is an inventor for six issued patents. Dr. Liu hasbeen an organizer formore than a dozen international meetings, such as, “Immunologic Activation,” a Nobel Forum meeting in Stockholm, Sweden,“Challenges of Global Pediatric Vaccine Development” held in Capetown, South Africa,(a Keystone Symposia meeting co-sponsored by the Bill & Melinda Gates Foundation and the Foundation for NIH Grand Challenges in Global Health),and “Emerging Infectious Diseases” at the Cold Spring Harbor Asia site in Suzhou, China. Prof. Dr. Her Royal Highness Princess Chulabhorn of Thailand invited Dr. Liu to join her in leading the Special Opening Segment of the First Joint Meeting of Ministers of Environment and Health from the ASEAN countries in August 2007. Her research has focused on novel technologies for vaccines and immune treatments for cancer. She pioneered the development of DNA vaccines, which are now in clinical trials for many human diseases and have been licensed for veterinary applications. She also was an innovator in the field of bispecific antibodies to activate T cells for tumor cell killing.

Dr. Liu was named one of “The 50 Most Important Women Scientists” by Discover magazine in November 2002. She did foundational work demonstrating the ability of bispecific antibodies to harness T cells to kill tumor cells. Her pioneering work in the area of DNA vaccines has led to her receipt of honorary lectureships, including the Rose Lectureship at Columbia University College of Physicians and Surgeons (1993), the Inaugural Saul Krugman Memorial Lecture at New York University (1996), the M. R. Hilleman Lecture at Children’s Hospital of Pennsylvania (1997), the Walter F. Enz Memorial Lecture Series at The University of Kansas (1999), the Oon International Fellowship in Preventive Medicine at Cambridge University, England (2000), and the Karolinska Research Lecture series at the invitation of the Nobel Committee (Sept. 2001).

Pele Choi-Sing Chong (Ph.D.)

Learn more

Pele Choi-Sing Chong (Ph.D.)

Biography

Dr. Chong obtained his BSc (1978) and PhD (1983) from the department of Biochemistry in the University of Alberta, Edmonton, Canada. He was trained as a protein chemist and specialized in peptide synthesis for protein structure and function studies. Dr. Chong spent 2.5 years as a postdoctoral fellow at the University of British Columbia, then worked 15 years in Toronto Connaught Laboratory Limited (now called Sanofi Pasteur) in human vaccine research and development. During his tenure there, Dr. Chong had developed two human vaccines, ProHibit against H. influenzae type b (Hib) and the component pertussis vaccine. Dr. Chong left Sanofi Pasteur in 2000 and joined United Biomedical Inc. (UBI), New York as the Vice President and the Chief Scientific Officer of UBI-Asia where he helped developing two animal vaccines: synthetic peptide-based vaccines against FMDV and Boar Taint. In June/2003, Dr. Chong was recruited and joined National Health Research Institutes (NHRI) as the Director and Distinguished Investigator to develop and establish the Vaccine Research and Development Center (VRDC). To facilitate and implement the Taiwanese Government Vaccine R&D, Self-Manufacturing and Supply strategic plans, VRDC starts from 1 person (Dr. Chong) and now has >140 staff operating as a fully integrated Biotech-like organization. During the last 10 years in NHRI, Dr. Chong has established the first Asian GMP pilot plants fully compliance with PIC/S guidelines, initiated and completed 2 vaccine candidates (MDCK cell-based H5N1 flu vaccine and Vero cell-based EV71 vaccine) human phase I clinical trials. In addition, Dr. Chong and his team have developed a novel lipoprotein platform technology for meningococcal group B vaccine development that has IND approval by Taiwan TFDA.Dr. Chong has authored published over 200 original research articles and has over 100 patents filed and/or granted. Some of these research results have been technology transfer to Taiwan companies.

Hiroshi Kiyono (D.D.S.  Ph.D.)

Learn more

Hiroshi Kiyono (D.D.S.  Ph.D.)

Education

1977 D.D.S. Nihon University School of Dentistry at Matsudo, Japan

1983 Ph.D. University of Alabama at Birmingham Medical Center (UAB), USA

Career

1984‐1987 Research and Clinical Assistant Professor, Department of Oral Biology, UAB

1986‐1987 Visiting Senior Scientist, Max-Planck Institute for Biology

1989‐1990 Associate Professor, Departments of Oral Biology and Microbiology, UAB

1991‐2003 Professor, Departments of Oral Biology and Microbiology, UAB

1994‐2003 Professor and Chairman, Department of Mucosal Immunology, Research Institute for Microbial Diseases, Osaka University

2002-Present Professor and Director, Division of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT)

2007-2010 Associate Dean, IMSUT

2011-2015 Dean, IMSUT

2011-Present Professor and Director, International Research and Development Center for Mucosal Vaccines, IMSUT

2016-Present Project Professor, Graduate School of Medicine, Chiba University

Award

1984 NIH New Investigator Research Award

1988 NIH Research Career Development Award

2005 ISI Highly Cited Researcher’s List

2007 The 51st Dr. Hideyo Noguchi Memorial Medical Science Award

2007 The Japanese Society for Vaccinology, Takahashi Award

2009 The Japanese Society for Food Immuology, Distinguished Scientist Award

Biography

Dr. Kiyono obtained his dental degree (D.D.S.) from Nihon University, and Ph. D. from the University of Alabama at Birmingham (UAB). His background as a dentist combined with extensive research experience in the field of Mucosal Immunology at UAB, Max-Planck Institute, Osaka University and now, the University of Tokyo makes him exceptionally well qualified to discuss the current and future directions of mucosal immunology and mucosal vaccine. To reflect his scientific contribution, he was listed in the ISI Highly Cited Researchers’ List and selected for the past President of Society for Mucosal Immunology. He received several prestigious awards including NIH New Investigator Research Award, NIH Research Career Development Award, The Japanese Society for Vaccinology Takahashi Award and Hideyo Noguchi Memorial Medical Science Award. He has a total of 485 publications in peer review journals and edited a total of 20 books. He was Dean of the Institute of Medical Science, the University of Tokyo and is currently its Director and Professor for International Research and Development Center for Mucosal Vaccines and Department of Microbiology and Immunology. Concurrently, he engages in a Project Professorship at Chiba University and an Adjunct Research Professorship at the University of Alabama at Birmingham (UAB).

Jerome H. Kim (M.D.)

Director General of International Vaccine Institute (IVI)

Learn more

Jerome H. Kim (M.D.)

Director General of International Vaccine Institute (IVI)

Biography

Jerome H. Kim is an international expert on the evaluation and development of vaccines. He has strong scientific experience spans basic research through advanced clinical development. A graduate of University of Hawaii (B.A.) and Yale University(M.D.); Dr. Kim completed Internal Medicine and Infectious Diseases training at Duke University Medical Center. Dr. Kim was Principal Deputy and Chief, Laboratory of Molecular Virology and Pathogenesis at U.S. Military HIV Research Program (MHRP) and also served as the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Materiel Development Activity, Fort Detrick, MD. He led the Army's Phase III HIV vaccine trial (RV144) that was the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates and HIV sequence changes associated with vaccination. Dr. Kim’s research interests include HIV molecular epidemiology, host genetics, and HIV vaccine development. He has authored over 160 publications and received the John Maher Award for Research Excellence from the Uniformed Services University of the Health Sciences in 2013.

Dr. Kim is a Professor of Medicine at the Uniformed Services University of the Health Sciences and an Adjunct Professor of Graduate School of Public Health of Seoul National University. He is a Fellow of the American College of Physicians and the Infectious Diseases Society of America.

Peter Khoury

SPO of Bill & Melinda Gates Foundation

Learn more

Peter Khoury

SPO of Bill & Melinda Gates Foundation

Biography

Peter H. Khoury is a Senior Program Officer, Life Sciences Partnerships within the Global Health Office of the President, for the Bill & Melinda Gates Foundation. His responsibilities involve working with vaccine manufacturers to explore ways to offer high quality, low cost vaccines to the world’s poorest populations. Peter obtained his doctorate in Microbiology from Syracuse University and also holds a MBA from Cornell University's Johnson Graduate School of Management in general management.

Prior to joining the Gates Foundation, Peter spent 20 years in various positions of increasing responsibility with Merck and Co. and Baxter International. His responsibilities have included business development, global marketing, government and institutional sales, product management, database and direct marketing, and global strategy development.

Baik Lin Seong (Ph.D.)

Professor of Yonsei University
Director of Vaccine Translational Research Center

Learn more

Baik Lin Seong (Ph.D.)

Professor of Yonsei University
Director of Vaccine Translational Research Center

Biography

Director of Vaccine Translational Research Center(VTRC) at Yonsei University, works on research and development of vaccines and protein folding platforms. He established scientific experience from basic molecular biology to pre-clinical development of biopharmaceuticals including vaccines and therapeutic proteins. He received B.S. from Seoul National University (1977), M.S. from KAIST (1979), Korea, and PhD from MIT (1988). After postdoctoral training at the University of Oxford, UK (1988-1992), he joined Aviron, a venture company in California, US, which was later acquired by MedImmune. After coming back to Korea, Dr. Seong served as director of the Institute of Biological Sciences of Hanhyo Institute of Technology (1993-1998), a biotechnology R&D initiative from one of the Korean economic conglomerates. As CEO of Protheon (2000-2009), Dr. Seong developed novel concepts of protein folding, which is instrumental for the development of recombinant vaccines. He represented the Korean Government in the Ad Hoc Group Meeting of Biological Weapons Convention (BWC) at United Nation in Geneva (2000-2008). As an expert on rational vaccine design, he continues to work on designing universal flu vaccine, assembly of virus-like particles (VLPs) and recombinant vaccines for viral and microbial infections. His work was recognized by the Hantaan research award from Hantaan Research Foundation (2000), and by Distinguished Merit Award from the Korean Government (2013).

Young Chul Sung (Ph.D.)

Professor, Pohang University of Science and Technology

Chairman and founder of Genexine Ltd.

Learn more

Young Chul Sung (Ph.D.)

Professor, Pohang University of Science and Technology

Chairman and founder of Genexine Ltd.

Biography

Dr. YC Sung received his Ph.D. degree in the department of biochemistry, University of Minnesota in 1988. After finishing his postdoctoral research at Dana Farber Cancer institute, Harvard Medical School, he became a professor at Pohang University of Science and Technology (POSTECH) in the Department of Life Science in 1989. Since then, he has conducted extensive research in the field of cellular immunology. One of his specialties is developing innovative DNA vaccines for treating cancers & infectious diseases. He had also invented Ab-fusion technology, called hyFc, to develop long-acting agonistic, innovative bio-drugs. In 1999, he established laboratory-based biotech company, called Genexine, which became a public firm by listing in the KOSTOCK in 2009. Recently, he has expanded his research to cancer gene therapy including CAR-engineered Natural Killer cells and engineered mesenchymal stem cells. In particular, he has managed to expand his research from mouse model to non-human primate, and ultimately to human patients (from bench to clinic). Currently, he is conducting several clinical trials with new drug candidates he developed. Among them, 5 different innovative bio-drugs are under clinical trial of phase 2. Through many years of experiences in academia and industry, he has established a global collaboration network among universities, hospitals, and companies for pioneering next generation of bio-drugs to save the lives of patients with hard-to-cure diseases.